Sun Pharmaceutical Industries Limited

18%

ACS data for 12 months ended Mar 2025 A diversified revenue base Emerging Markets Formulations 18% Rest of World (RoW)# Formulations 14% FY25 Sales Rs 520 Bn India Formulations 33% API & Others

14%

diversified revenue base Emerging Markets Formulations 18% Rest of World (RoW)# Formulations 14% FY25 Sales Rs 520 Bn India Formulations 33% API & Others 4% US Formulations 31% © Sun Pharmace

Rs 520

enue base Emerging Markets Formulations 18% Rest of World (RoW)# Formulations 14% FY25 Sales Rs 520 Bn India Formulations 33% API & Others 4% US Formulations 31% © Sun Pharmaceutical Industries Li

33%

Formulations 18% Rest of World (RoW)# Formulations 14% FY25 Sales Rs 520 Bn India Formulations 33% API & Others 4% US Formulations 31% © Sun Pharmaceutical Industries Limited. All Rights Reserved

rs 4

8% Rest of World (RoW)# Formulations 14% FY25 Sales Rs 520 Bn India Formulations 33% API & Others 4% US Formulations 31% © Sun Pharmaceutical Industries Limited. All Rights Reserved. 5 # Include

31%

# Formulations 14% FY25 Sales Rs 520 Bn India Formulations 33% API & Others 4% US Formulations 31% © Sun Pharmaceutical Industries Limited. All Rights Reserved. 5 # Includes Western Europe, Cana

19%

rd of growth (All Figures in Rs Bn) CAGR for FY10-FY25 520 153 120 323 272 40 Sales CAGR 19% 79 70 14 EBITDA CAGR 18% 48 40 14 Adjusted Net Profit CAGR 16% FY10 FY15 FY20 FY25 FY10

16%

323 272 40 Sales CAGR 19% 79 70 14 EBITDA CAGR 18% 48 40 14 Adjusted Net Profit CAGR 16% FY10 FY15 FY20 FY25 FY10 FY15 FY20 FY25 FY10 FY15 FY20 FY25 141 119 50 66 56 8 Operating

21%

FY25 FY10 FY15 FY20 FY25 FY10 FY15 FY20 FY25 141 119 50 66 56 8 Operating Cash Flow CAGR 21% 50 33 5 Free Cash Flow CAGR 24% 20 17 6 FY10 FY15 FY20 FY25 FY10 FY15 FY20 FY25 FY10 FY1

24%

FY20 FY25 141 119 50 66 56 8 Operating Cash Flow CAGR 21% 50 33 5 Free Cash Flow CAGR 24% 20 17 6 FY10 FY15 FY20 FY25 FY10 FY15 FY20 FY25 FY10 FY15 FY20 FY25 Adjusted EPS (Rs/Share

73.1%

Strong profitability and return ratios Gross Margin # EBITDA Margin Adjusted Net Profit Margin 73.1% 75.4% 77.7% 79.3% 29.0% 19.8% 19.7% 20.8% 22.8% 26.9% 26.9% 26.5% FY22 FY23 FY24 FY2

75.4%

profitability and return ratios Gross Margin # EBITDA Margin Adjusted Net Profit Margin 73.1% 75.4% 77.7% 79.3% 29.0% 19.8% 19.7% 20.8% 22.8% 26.9% 26.9% 26.5% FY22 FY23 FY24 FY25 FY22

“22 US business: revenue progression Sales in Rs Bn 162 153 135 114 101 FY21 FY22 FY23 FY24 FY25 23 ANDA & NDA pipeline ANDAs filed and approved (cumulative) NDA filed and approved (cumulative) 595 605 616 635 659 501 512 519 531 541 64 55 67 67 54 54 70 57 65 51 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Cumulative products filed Cumulative products approved Cumulative products filed Cumulative products approved © Sun Pharmaceutical Industries Limited.”

“(All data as of 31-Mar-2025) 24 India Business 33% of FY25 Revenues © Sun Pharmaceutical Industries Limited.”

“27 Source: AIOCD AWACS MAT Mar 2025 India: revenue progression Sales in Rs Bn Therapeutic breadth** 169 149 136 128 103 FY21 FY22 FY23 FY24 FY25 Others 4% Opthalmology 3% Urology 3% Neuro-Psychiatry 20% Gynaecology 4% Dermatology 4% Vitamins / Minerals / Nutrients 5% Respiratory 5% Anti-Infectives 6% Pain / Analgesics 7% Market Share 8.3% Cardiology 17% Diabetology 8% Gastroenterology 14% ** As per AIOCD AWACS MAT Mar 2025 © Sun Pharmaceutical Industries Limited.”

“of medical representatives Sales per representative (Rs mn) 30 Emerging Markets 18% of FY25 Revenues © Sun Pharmaceutical Industries Limited.”

“32 Rest of World (Western Europe, Canada, Japan, ANZ, Israel & other markets) 14% of FY25 Revenues © Sun Pharmaceutical Industries Limited.”

“Strong brand equity Strong brand equity in 4 countries Sales force Promoted through dedicated sales force in each market Strong positioning Amongst top 10 consumer healthcare companies in India, Romania, Nigeria & Myanmar 36 Active Pharmaceutical Ingredients (API) 4% of FY25 Revenues © Sun Pharmaceutical Industries Limited.”

“39 Research & Development Cumulative R&D spend of ~Rs 300 Bn to date R&D spend R&D spend at 6.2% of sales for FY25 Specialty R&D Global development capabilities incl.”

“40 R&D investments R&D investments Filings and approvals 6.5% 5.8% 5.5% 6.7% 6.2% ANDA NDA/BLA DMF/CEP Patents** 21.5 22.2 23.7 31.8 32.5 659 70 542 529 3,229 57 401 2,459 FY21 FY22 FY23 FY24 FY25 Filed Approved Filed Approved Filed Approved Filed Granted R&D investments (Rs Bn) R&D investments (% of sales) © Sun Pharmaceutical Industries Limited.”

“# FY25 - Adjusted for Rs 10.6 Bn provision related to (i) Opioid settlement = Rs 3,162 mn (ii) Concert Restructuring =Rs 440 mn (iii) Taro Restructuring =Rs 580 mn (iv) Investment in Lyndra =Rs 2,597 mn (v) Deferred tax adjustments =Rs 3,775 mn © Sun Pharmaceutical Industries Limited.”

“47 Sales split In Rs Bn Sales 332 384 433 478 520 21 49 58 101 103 21 55 67 114 128 22 60 79 135 136 22 67 86 153 149 23 72 94 162 169 FY21 FY22 FY23 FY24 FY25 India Formulations US Formulations Emerging Markets Rest of World API+Others © Sun Pharmaceutical Industries Limited.”

Source

3

Note

1

Net Profit Adjustment

1

Note

(1) As of July 08, 2025, using spot exchange rate of INR /USD = 85.70 # Includes Western Europe, Canada, Japan, Australia & New Zealand, Israel and other markets. * Source: IQVIA data for 12 months ended Mar 2025 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 10 Driving sustainable long term growth • Achieve critical mass in key markets • Embed sustainability practices in business • Actionable targets on sustainability Sustainable growth t s o C • Optimize operational costs • Leverage benefits of vertically integrated operations i p h s r e d a e l i n v e s t m e n t s p r o f i t a b i l i t y & l B a a n c e Business development • Increase contribution of specialty and complex products • Direct future investments towards differentiated products • Use acquisitions to bridge gaps while yielding target ROI • Focus on access to novel products, technology or market presence © Sun Pharmaceutical Industries Limited. All Rights Reserved. 11 ESG Performance - FY 2023-24 Enviro

Source

1, 2 & 3 Sun Press Release 4 Levulan website © Sun Pharmaceutical Industries Limited. All Rights Reserved. 15 Innovative Therapies portfolio Treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. • ODOMZO was shown to shrink laBCC in almost 6 out of 10 patients (56%) in a clinical study. laBCC Patients were treated with ODOMZO® and followed for at least 18 months5 • Currently marketed in US, Canada, EU, Australia and Israel To increase tear production in patients with keratoconjunctivitis sicca (dry eye) • Phase 3 confirmatory study observed clinically and statistically significant improvements in tear production and ocular surface integrity in patients6 • Current Markets: US, Canada and India • Out-licensed to CMS for Greater China in June 2019 Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing catar

Source

5 Product Label 6 Sun Press Release 7 & 8 Product website 16 Innovative Therapies portfolio In combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). • YONSA® was shown in clinical studies to be an effective form of abiraterone acetate, and can be taken with or without food, in combination with methylprednisolone9 • Current Markets: US First and only product approved in the US for treating seizures in neonatal patients • NEOLEV2 study compared phenobarbital to levetiracetam in the first-line treatment of neonatal seizures. 24 hours following the administration, 73% vs. 25% were seizure-free in the respective groups10 • Current Markets: US For therapeutic solutions for long-term care (LTC) patients • Products using sprinkle technology for patients who have difficulty swallowing • Sprinkle versions of metoprolol (cardiology), rosuvastatin (cardiology) & duloxetine (neuro-psychiatry) • Current Markets: US • Treatment

Source

9, 10 & 11 Sun Press Release © Sun Pharmaceutical Industries Limited. All Rights Reserved. 17 Innovative Therapies pipeline Candidate Mechanism of action Unloxcyt anti-PD-L1 Nidlegy™ Immunocytokines Indication Preclinical Phase 1 Phase 2 Phase 3 Registration metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC melanoma & non- melanoma skin cancers Ilumya IL-23 Antagonist psoriatic arthritis Fibromun Innovative anti-cancer immunotherapy soft tissue sarcoma glioblastoma GL0034 GLP-1R Agonist Type 2 diabetes MM-II Liposomal intra- articular lubrication pain in osteoarthritis All candidates for global markets except Nidlegy™ where Sun is commercial partner for Europe, Australia & New Zealand. Nidlegy™ is a trademark of Philogen. Creating Lasting Value - Investor Presentation 18 Innovative Therapies Sales Specialty Sales (USD mn) 485 674 871 1,039 1,216 18.0 16.2 19.8 13.1 10.8 FY21 FY22 FY23 FY24 FY25 Specialty Branded Sales Specialty Sales (%) of Total Sales • US i

Net Profit Adjustment

# Q4FY24 - Adjusted for Rs 1,016 Mn related to the impact of Nigeria Forex loss Rs 784 mn & Japan restructuring cost Rs 232 mn FY24 - Adjusted for Rs 4.9 Bn related to (i) Impairment of intangible under development of Ache Labs = Rs. 1,492 mn (ii) Nigeria Forex loss =Rs 2,014 mn (iii) Alchemee restructuring cost =Rs 507 mn (iv) Lipitor West Virginia settlement =Rs 698 mn (v) Japan restructuring cost =Rs 232 mn Q4FY25 - Adjusted for Rs 7.4 Bn related to the (i) impact of Investment in Lyndra Rs 2,597 mn, (ii) Taro restructuring cost Rs 580 mn, (iii) Concert restructuring cost Rs 440 mn, (iv) Deferred tax adjustment Rs 3,775 mn FY25 - Adjusted for Rs 10.6 Bn related to the (i) Opioid settlement = Rs 3,162 mn (ii) Concert Restructuring =Rs 440 mn (iii) Taro Restructuring =Rs 580 mn (iv) Investment in Lyndra =Rs 2,597 mn (v) Deferred tax adjustment Rs 3,775 mn © Sun Pharmaceutical Industries Limited. All Rights Reserved. 52 Sales split Q4 FY25 Q4 FY25 Q4 FY24 CHANGE FY25 ( All Figures in R